Clinical Trials Logo

NSCLC clinical trials

View clinical trials related to NSCLC.

Filter by:

NCT ID: NCT03513666 Completed - NSCLC Clinical Trials

A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment

JS001
Start date: April 9, 2018
Phase: Phase 2
Study type: Interventional

JS001 combined with pemetrexed plus carboplatin for treatment of recurrent or advanced non-small-cell lung cancer with EGFR-mutation positive and T790M negative after progression on EGFR-TKI treatment:a multi-center, single arm phase II study

NCT ID: NCT03465241 Completed - NSCLC Clinical Trials

ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGS

Start date: October 21, 2017
Phase:
Study type: Observational

The second generation of high-throughput gene sequencing (NGS) is an important means of detecting the tumor DNA and circulating tumor DNA (ctDNA), which can detect trace ctDNA from smaller plasma samples. This project is chiefly to study the role of ctDNA dynamic monitoring of stage IIA to IIIA NSCLC by NGS technique to verify the prognostic predictive effect of ctDNA. And the investigators also wander the concordance of lung cancer related genes mutation map and frequency between primary tumors and infiltrated regional lymph nodes.

NCT ID: NCT03464032 Recruiting - Melanoma Clinical Trials

A Study of BCD-135 in Patients With Advanced Solid Tumors

Start date: October 31, 2017
Phase: Phase 1
Study type: Interventional

A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-135 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors

NCT ID: NCT03453307 Recruiting - NSCLC Clinical Trials

Drug Sensitivity Correlation Between Patient-Derived Organoid Model and Clinical Response in NSCLC Patients

Start date: January 30, 2018
Phase: N/A
Study type: Observational

This clinical study aims to evaluate the feasibility to predict clinical response of target therapy or chemotherapy drugs based on the ex vivo drug sensitivity data using patient-derived organoids.

NCT ID: NCT03448146 Completed - Nsclc Clinical Trials

A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction

Start date: August 2009
Phase: Phase 3
Study type: Interventional

This trial was to evaluate the efficacy of intratumoral PTS injection in alleviating airway obstruction and dyspnea by improving the percentage of lumen patency of patients with central air way NSCLC tumor severe obstruction.

NCT ID: NCT03428022 Recruiting - NSCLC Clinical Trials

Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC

AFLC
Start date: December 1, 2017
Phase: Phase 3
Study type: Interventional

Patients with advanced non-small cell lung cancer (NSCLC) who progress slowly after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors(EGFR-TKI)resistance will be treated with Apatinib and EGFR-TKI. The primary objective is the disease progression free survival of the patients.

NCT ID: NCT03416231 Recruiting - NSCLC Clinical Trials

Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)

Start date: November 30, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the effectiveness and safety of apatinib combined with docetaxel in NSCLC.

NCT ID: NCT03394118 Completed - NSCLC Clinical Trials

TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy

Start date: August 11, 2017
Phase: Phase 2
Study type: Interventional

In this trial, anti-tumor efficacy of TAGRISSO in NSCLC patients in whom T790 mutations are detected by liquid biopsy.

NCT ID: NCT03368222 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Pembrolizumab and SBRT in Metastatic Non-small-cell Lung Cancer Patients

PRIMING
Start date: January 2018
Phase: Phase 1
Study type: Interventional

This is a single centre non-randomised open label phase 1 trial of lung SBRT to part of a lung lesion in patients with advanced NSCLC in combination with pembrolizumab. This study will recruit up to 24 patients whose lung cancer has progressed beyond one line of palliative chemotherapy, and an EGFR or ALK inhibitor if an EGFR driver mutation or ALK gene rearrangement is present, respectively, and now requires further palliative systemic treatment.

NCT ID: NCT03353428 Withdrawn - Lung Cancer Clinical Trials

Intervention of Engineered Immune Effector T Cells Against Lung Cancer

Start date: November 15, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety of lung cancer specific cytotoxic lymphocytes (LC-CTLs). The secondary objectives are to evaluate the rate of successful LC-CTLs generation in vitro and determine the anti-lung cancer efficacy.